Procurement specifications for monoethanolamine (MEA; CAS 141-43-5; 2-aminoethan-1-ol; molar mass 61.08 g mol⁻¹) in cosmetic and pharmaceutical applications require a control framework that extends beyond amine assay, colour, and water content. MEA is a primary alkanolamine with a pKa of 9.55 for the protonated amine and a boiling point of 170.8 °C at 101.3 kPa. It is used in cosmetic carbomer neutralisation at loadings typically between 0.1 wt% and 1.0 wt%, in topical drug salt formation, and as a pH adjuster in dilute aqueous systems. The nitrosamine concern in MEA supply is not derived from MEA itself under normal liquid-phase storage or formulation; primary amines under nitrosating conditions preferentially form diazonium species or their decomposition products rather than stable N-nitrosamines. The purchasing risk is instead governed by trace secondary alkanolamines, principally diethanolamine (DEA; CAS 111-42-2), formed as a co-product in the ethylene oxide–ammonia alkoxylation train and only partially removed by fractional distillation. If DEA is present above a formulation-specific threshold and a nitrosating species is available, N-nitrosodiethanolamine (NDELA) can form in aqueous formulations. MEA buyers therefore must treat DEA content, nitrite/nitrate ingress, and nitrosamine method sensitivity as linked critical quality attributes rather than isolated release tests.

Where Does Nitrosamine Risk Actually Originate in MEA-Containing Systems?

Nitrosation proceeds through the reaction of a nitrosating agent with an unprotonated secondary amine. In aqueous cosmetic and pharmaceutical matrices, nitrous acid generated from nitrite under acidic conditions forms dinitrogen trioxide, which transfers NO⁺ to the secondary amine. The rate maximum for many secondary amines occurs in the pH 3.0–3.5 region, where both nitrous acid and dissolved nitrite are available and the amine is not fully protonated. MEA does not participate directly in this pathway to form a stable N-nitrosamine because the primary amine adduct rearranges through the diazonium route. Residual DEA in MEA is the critical nitrosatable amine. NDELA is classified by IARC as 2B possibly carcinogenic to humans, which drives the conservative orientation of raw-material specifications. NDELA formation is therefore possible when MEA with DEA impurity is combined with nitrite-containing water, preservative systems that release nitrite, nitrocellulose packaging components, or excipients with residual nitrite. The reaction rate is second-order in dissolved nitrite under conditions where dinitrogen trioxide formation is rate-limiting; this dependence means that reducing nitrite concentration by one order of magnitude lowers the initial nitrosation rate by approximately two orders of magnitude under otherwise constant pH, temperature, and amine activity.

Industrial MEA synthesis is operated with an ammonia-to-ethylene oxide molar ratio above 10:1 to suppress the consecutive reactions that form DEA and triethanolamine. The reaction is exothermic and is controlled in a tubular reactor with external cooling before the effluent enters ammonia recovery and vacuum fractionation. The distilled MEA quality depends on the efficiency of the final vacuum fractionation; residual DEA is the most likely related substance because its boiling point is roughly 98 °C higher than MEA. A well-operated column can achieve DEA content below 0.1 wt%, but process upsets such as loss of vacuum or bottom-level excursions can increase DEA carryover. Production-scale separation exposes a key trade-off: the relative volatility gap between MEA and DEA is sufficient for fractional separation but not absolute. Buyers should not infer purity from total amine assay alone; a total amine titration can be within specification while DEA is present at a level that is unacceptable for a nitrosamine-sensitive aqueous system.

Pharmacopoeial and regulatory control frameworks for MEA require buyers to distinguish between the primary amine assay and the secondary amine impurity profile. The current European Pharmacopoeia and United States Pharmacopeia general chapters establish chromatographic approaches for related substances in amino alcohols; the applicable monograph for monoethanolamine where adopted sets a specific diethanolamine limit that should be verified against the current official edition. The safety assessment for cosmetics under Regulation (EC) No 1223/2009, Annex I Part A point 4 requires the responsible person to consider impurities and traces, including substances produced by interaction between ingredients. Nitrosamine formation is not solely a raw-material problem; it is a matrix-dependent reaction. A MEA lot that passes DEA limits at release can still generate NDELA if the finished formulation contains nitrite at parts-per-million concentrations and an acidic pH. Pharmaceutical buyers align with ICH M7(R1) for mutagenic impurities; the threshold of toxicological concern is 1.5 µg/day for a single mutagenic impurity, but nitrosamine-specific acceptable intakes are often lower. EMA and FDA nitrosamine guidance require marketing authorisation holders to risk-assess nitrosamines across drug products and to confirm control with validated analytical methods. Although MEA is not a secondary amine, it is included in such assessments wherever its impurity profile or degradation pathway can contribute a nitrosating or nitrosatable matrix component.

Provenance, Storage, and Analytical Audit Trail in MEA Procurement

MEA is hygroscopic and reacts with atmospheric carbon dioxide to form carbamate species. Uncontrolled storage in partially filled drums or vented tanks changes the free-amine concentration and may shift the apparent moisture balance. MEA has a freezing point near 10.3 °C; unheated outdoor storage in temperate climates can produce solid or slush, leading to line blockages and concentration stratification after partial thawing. Suitable transfer systems use 316L stainless steel or high-density polyethylene lines, nitrogen blanketing, and desiccant filters on breather vents. Carbon steel and copper alloys are incompatible because MEA can complex transition metals and generate coloured oxidation products; this is a known batch-to-batch failure mode when storage tanks are re-qualified without verifying metallurgy. For nitrosamine-sensitive end uses, the supplier audit should verify that transfer lines are not shared with DEA or morpholine without documented flush protocols. Cross-contamination with a secondary amine at the storage terminal can introduce a nitrosatable impurity that does not originate from the ethylene oxide process.

Analytical confirmation of MEA batches requires two distinct operations: related amine profiling and nitrosamine-specific measurement. Gas chromatography with flame ionisation detection after derivatisation allows separation of MEA, DEA, and triethanolamine. Liquid chromatography-tandem mass spectrometry in atmospheric pressure chemical ionisation mode provides the sensitivity needed for NDELA at trace levels. Method validation should follow ICH Q2(R1) and be performed under ISO/IEC 17025:2017 laboratory accreditation. A practical acceptance protocol for high-risk cosmetic and pharmaceutical use includes the parameters in Table 1.

In a high-viscosity carbomer gel neutralised with MEA, pH uniformity is not achieved instantaneously. Neutraliser droplets create local alkaline zones, while the bulk gel near acid carbomer remains below pH 4.0. If sodium nitrite is present as a trace impurity from an excipient or water source, the low-pH zone provides a kinetic window for NDELA formation before the formulation equilibrates. This is a mixing-dependent risk, not simply a formulation-dependent risk. Anchor mixers with centre-mounted propellers may leave stagnant acidic regions in the upper periphery of a 500 L vacuum kettle. Slow sweep agitation followed by short high-shear dispersion reduces the dwell time of low-pH domains. Formulators should evaluate neutraliser addition rate, mixer tip speed, and final pH ramp rather than assuming uniform pH from a single grab sample. This production-scale failure mode is documented in general mixing literature, although published data for this specific configuration is limited.

When Monoethanolamine Is Used in Transdermal or Parenteral Formulation Routes

Transdermal and parenteral products carry additional nitrosamine risk because the dose, permeation area, or route of delivery can reduce tolerable impurity mass. A topical cream applied over large body surfaces may deliver more NDELA per day than a small oral dose if the formulation contains a nitrosatable impurity. For pharmaceutical development, the nitrosamine risk assessment must consider the maximum daily dose, route-specific bioavailability, and whether the product contains primary amines as masking agents or pH adjusters. The toxicological assessment follows ICH M7(R1) limits and compound-specific acceptable intakes published by regional regulators, but the analytical limit must be translated into a concentration limit based on product mass and maximum daily exposure. For a transdermal product with a high daily application mass, this conversion can push the required NDELA detection limit into the sub-100 ng/g range. Published data for this specific configuration is limited; therefore, the analytical method must be qualified at the intended limit using replicate matrix spikes and a verification of recovery in the target formulation.

Parenteral use of MEA as a pH-adjusting agent is less common than topical use because alternate inorganic alkalizers are widely available. When MEA is specified for a parenteral or ophthalmic formulation, the supplier must provide documented absence of nitrosating impurities and a validated nitrosamine method. Rubber stoppers, sterilisation autoclave conditions, and terminal gamma irradiation can all affect nitrosamine formation potential. Terminal gamma irradiation of aqueous formulations produces hydroxyl radicals and solvated electrons, which can modify amine impurities and potentially interact with nitrite. If the formulation cannot be sterilised by filtration, the risk assessment should include forced-degradation studies in the final container closure system.

Supplier qualification for MEA should not rely on a single CoA. A coherent control strategy evaluates the distillation process, the analytical method used to certify DEA, the limit of detection for that method, the packaging atmosphere, and the transfer history. Buyers should request the lot-specific chromatographic integration for DEA and the derivatisation procedure because reporting a result as “below the limit” is insufficient when the limit itself is above the formulation-specific threshold. If the supplier uses an in-house titration assay for total amine but certifies DEA by a secondary method with a detection limit of 0.5 wt%, a nitrosamine-sensitive buyer cannot distinguish between 0.05 wt% and 0.45 wt% DEA, and must either qualify a more sensitive laboratory or reject the lot for high-risk use. This is a common audit finding in cosmetic raw-material supply chains. Contract laboratories performing nitrosamine analysis should provide extracted-ion chromatograms, matrix recovery, and a statement of measurement uncertainty under ISO/IEC 17025:2017. Supplier quality management under ISO 9001:2015, clause 8.4, requires documented control of externally provided raw materials; this should be supplemented by audit evidence for MEA distillation and transfer.

Nitrite Scavenger Addition to MEA-Neutralised Carbomer Gels

Ascorbic acid and sodium metabisulfite are used as nitrosation inhibitors in cosmetic and pharmaceutical systems. Ascorbic acid competes with the secondary amine for nitrous acid by reducing it to nitric oxide and forming dehydroascorbic acid. The stoichiometric demand is not one-to-one in a formulation with significant oxygen ingress because dissolved oxygen reoxidises nitric oxide to nitrogen dioxide and regenerates nitrosating equivalents. A molar excess of ascorbic acid over nitrite is required, and the required excess increases at low pH where ascorbic acid is less stable. Sodium metabisulfite can also suppress nitrosation but introduces sulfite sensitivity and may reduce colour stability. In a carbomer gel neutralised with MEA, the scavenger must be distributed before low-pH regions persist; post-neutraliser addition of scavenger does not fully protect the gel because the reactive window has already occurred. The formulation development report should record pH profile before and after neutralisation, scavenger concentration, and freeze-thaw cycling because nitrosamine formation can continue slowly at ambient storage if nitrite and secondary amines are both present. Published data for this specific configuration is limited, so forced-degradation batches at 40 °C and 75% RH are used to confirm that the nitrosamine level remains below the acceptable intake across the product shelf life under ICH Q1A(R2).